Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + Gemcitabine in Elderly or Unfit Patients with Advanced NSCLC (Phase II)
2007-003075-39Phase 2Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Jun 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in non-small cell lung cancer (NSCLC), sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoints: Activity and toxicity of docetaxel + gemcitabine every 15 days and Median survival. Started Jun 2007; status: active.
02
Drugs
docetaxelgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-003075-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003075-39.